Neuroprotection Trials in Traumatic Brain Injury
- 16 February 2016
- journal article
- review article
- Published by Springer Science and Business Media LLC in Current Neurology and Neuroscience Reports
- Vol. 16 (4), 1-8
- https://doi.org/10.1007/s11910-016-0625-x
Abstract
Traumatic brain injury (TBI) is a significant cause of mortality and morbidity worldwide. Current treatment of acute TBI includes surgical intervention when needed, followed by supportive critical care such as optimizing cerebral perfusion, preventing pyrexia, and treating raised intracranial pressure. While effective in managing the primary injury to the brain and skull, these treatment modalities do not address the complex secondary cascades that occur at a cellular level following initial injury and greatly affect the ultimate neurologic outcome. These secondary processes involve changes in ionic flux, disruption of cellular function, derangement of blood flow and the blood-brain barrier, and elevated levels of free radicals. Over the past few decades, numerous pharmacologic agents and modalities have been investigated in an attempt to interrupt these secondary processes. No neuroprotective agents currently exist that have been proven to improve neurologic outcome following TBI. However, these trials have contributed significantly to the understanding of the clinical sequelae of TBI and to improvements in the quality of care for TBI. With the experience and insights that have been accrued with the trials to date, we will be able to optimize future trial designs and refine established neurologic endpoints to better identify new therapeutic agents and further improve neurologic outcomes from this often devastating condition.Keywords
This publication has 72 references indexed in Scilit:
- Traumatic Brain InjuryJama-Journal Of The American Medical Association, 2013
- A Review of Neuroprotection Pharmacology and Therapies in Patients with Acute Traumatic Brain InjuryCNS Drugs, 2012
- Very early hypothermia induction in patients with severe brain injury (the National Acute Brain Injury Study: Hypothermia II): a randomised trialThe Lancet Neurology, 2011
- Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategiesTrends in Pharmacological Sciences, 2010
- d-Cycloserine improves functional outcome after traumatic brain injury with wide therapeutic windowEuropean Journal of Pharmacology, 2010
- Safety and Tolerability of Cyclosporin A in Severe Traumatic Brain Injury Patients: Results from a Prospective Randomized TrialJournal of Neurotrauma, 2009
- Update of the Stroke Therapy Academic Industry Roundtable Preclinical RecommendationsStroke, 2009
- Dosing and safety of cyclosporine in patients with severe brain injuryJournal of Neurosurgery, 2008
- Progesterone exerts neuroprotective effects after brain injuryBrain Research Reviews, 2008
- Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trialCritical Care, 2008